Page 102 - Read Online

Harangi et al. LDL apheresis or PCSK9 inhibition, or both?

REFERENCES Antibody-mediated disruption of the interaction between PCSK9 and
the low-density lipoprotein receptor. Biochem J 2009;419:577-84.
1. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito 9. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era
MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, of lipid lowering therapy. World J Cardiol 2017;9:76-91.
Lopes-Virella M, Watts GF, Wierzbicki AS; American Heart 10. Lappegård KT, Enebakk T, Thunhaug H, Hovland A. Transition from
Association Atherosclerosis, Hypertension, and Obesity in Young LDL apheresis to evolocumab in heterozygous FH is equally effective
Committee of Council on Cardiovascular Disease in Young, in lowering LDL, without lowering HDL cholesterol. Atherosclerosis
Council on Cardiovascular and Stroke Nursing, Council on 2016;251:119-23.
Functional Genomics and Translational Biology, and Council on 11. Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB,
Lifestyle and Cardiometabolic Health. The agenda for familial Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V,
hypercholesterolemia: a scientific statement from the American Heart Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du
Association. Circulation 2015;132:2167-92. Y, Manvelian G. Alirocumab in patients with heterozygous familial
2. Ahmad Z, Adams-Huet B, Chen C, Garg A. Low prevalence of hypercholesterolaemia undergoing lipoprotein apheresis: the
mutations in known loci for autosomal dominant hypercholesterolemia ODYSSEY ESCAPE trial. Eur Heart J 2016;37:3588-95.
in a multiethnic patient cohort. Circ Cardiovasc Genet 2012;5:666-75. 12. Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound
3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, of lipoproteins after LDL-apheresis. Kinetics and estimation of mean
Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, lipoprotein levels. Atherosclerosis 2000;152:519-26.
Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren 13. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective
WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force removal of low density lipoprotein by plasmapheresis in familial
Members; Additional Contributor. 2016 ESC/EAS guidelines for the hypercholesterolemia. Arteriosclerosis 1985;5:613-22.
management of dyslipidaemias. Eur Heart J 2016;37:2999-3058. 14. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL,
4. Repas TB, Tanner JR. Preventing early cardiovascular death in Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins
patients with familial hypercholesterolemia. J Am Osteopath Assoc R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk
2014;114:99-108. of coronary heart disease, stroke, and nonvascular mortality. JAMA
5. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele 2009;302:412-23.
RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen- 15. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein
Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, EA. Low-density lipoprotein cholesterol-lowering effects of AMG
Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries 145, a monoclonal antibody to proprotein convertase subtilisin/
SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, kexin type 9 serine protease in patients with heterozygous familial
Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund hypercholesterolemia: the Reduction of LDL-C with PCSK9
O, Chapman MJ; European Atherosclerosis Society Consensus Inhibition in Heterozygous Familial Hypercholesterolemia Disorder
Panel on Familial Hypercholesterolaemia. Homozygous familial (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.
hypercholesterolaemia: new insights and guidance for clinicians to 16. Bosch T, Gahr S, Belschner U, Schaefer C, Lennertz A, Rammo J;
improve detection and clinical management. A position paper from the DALI Study Group. Direct adsorption of low-density lipoprotein by
Consensus Panel on Familial Hypercholesterolaemia of the European DALI-LDL-apheresis: results of a prospective long-term multicenter
Atherosclerosis Society. Eur Heart J 2014;35:2146-57. follow-up covering 12,291 sessions. Ther Apher Dial 2006;10:210-8.
6. Page MM, Watts GF. Emerging PCSK9 inhibitors for treating 17. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K,
dyslipidaemia: buttressing the gaps in coronary prevention. Expert Takegoshi T. Long-term efficacy of low-density lipoprotein apheresis
Opin Emerg Drugs 2015;20:299-312. on coronary heart disease in familial hypercholesterolemia. Hokuriku-
7. Bambauer R, Bambauer C, Lehmann B, Latza R, Schiel R. FH-LDL-Apheresis Study Group. Am J Cardiol 1998;82:1489-95.
LDL-apheresis: technical and clinical aspects. Sci World J 18. Mellwig KP, Pulawski E, Horstkotte D, van Buuren F. Lipid apheresis:
2012;2012:314283. oxidative stress, rheology, and vasodilatation. Clin Res Cardiol Suppl
8. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. 2012;7:45-9.

Vessel Plus ¦ Volume 1 ¦ June 27, 2017 95